Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.

@article{Kuropkat2002FollowupWS,
  title={Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.},
  author={Christiane Kuropkat and Burkard M. Lippert and Jochen Werner},
  journal={Oncology},
  year={2002},
  volume={63 3},
  pages={280-5}
}
OBJECTIVE Finding tumor markers for disease progression, and especially development of distant metastases, is desirable for patients with squamous cell carcinoma of the head and neck (SCCHN). Elevated serum levels of Cyfra 21-1 (cytokeratin fraction 21-1) have been frequently associated with disease progression in patients with lung cancer. In SCCHN, Cyfra 21-1 has not been established as a routine tumor marker yet, probably due to difficulties in finding the appropriate cut-off for the serum… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…